Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211130 · ClinicalTrials.gov registry record · Early Phase 1
Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors
A Early Phase 1 study, sponsored by University of Missouri, Kansas City.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT03211130: Completed Early Phase 1 study, sponsored by University of Missouri, Kansas City.
NCT03211130 is a Early Phase 1 study that has completed, run by University of Missouri, Kansas City. The registered enrollment target is 30 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03211130, a Early Phase 1 study, has completed, sponsored by University of Missouri, Kansas City.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study evaluated the feasibility and acceptability of using a SystemCHANGE intervention in older adult stroke survivors to improve medication adherence. Half the participants will receive the SystemCHANGE intervention, while the other half will receive the attention-control education intervention.
Primary Outcome
Open ended questionnaire
Interventions
- BEHAVIORAL Attention-Control
- BEHAVIORAL SystemCHANGE™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-28 |
| Est. Completion | 2018-05-24 |
| Phase | Early Phase 1 |
What the finished NCT03211130 record still lists
NCT03211130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 2 interventions - of which Attention-Control is the first listed.
NCT03211130 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03211130 about?
NCT03211130 is a clinical study titled "Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors". This study evaluated the feasibility and acceptability of using a SystemCHANGE intervention in older adult stroke survivors to improve medication adherence. Half the participants will receive the SystemCHANGE intervention, while the other half will receive the attention-control education interventio...
What is the current status of trial NCT03211130?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2017-11-28. Estimated completion is 2018-05-24.
What interventions are being tested in trial NCT03211130?
The interventions under investigation include: Attention-Control (BEHAVIORAL), SystemCHANGE™ (BEHAVIORAL).
Who is sponsoring clinical trial NCT03211130?
This trial is sponsored by University of Missouri, Kansas City, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03211130's enrollment target sits among peer trials
30 807th of 2000 higher than 1,075 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI